Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.

van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG.

Pharmacogenomics J. 2013 Oct;13(5):389-95. doi: 10.1038/tpj.2013.25. Epub 2013 Jul 16. Review. Erratum in: Pharmacogenomics J. 2014 Aug;14(4):400.

PMID:
23856855
3.

The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.

Ben Fredj R, Gross E, Ben Ahmed S, Hassine H, Saguem S.

Pathol Biol (Paris). 2009 Sep;57(6):470-6. doi: 10.1016/j.patbio.2008.05.001. Epub 2008 Jul 10.

PMID:
18619742
4.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Feb;44(1):13-23. doi: 10.1053/j.seminoncol.2017.02.008. Epub 2017 Feb 11.

PMID:
28395758
5.

Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

van Kuilenburg AB, Häusler P, Schalhorn A, Tanck MW, Proost JH, Terborg C, Behnke D, Schwabe W, Jabschinsky K, Maring JG.

Clin Pharmacokinet. 2012 Mar 1;51(3):163-74. doi: 10.2165/11595880-000000000-00000.

PMID:
22339448
6.

Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.

Thomas F, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, Bonadona A, Penel N, Goncalves A, Delord JP, Toulas C, Chatelut E.

Clin Pharmacol Ther. 2016 Feb;99(2):235-42. doi: 10.1002/cpt.210. Epub 2015 Nov 10.

PMID:
26265035
8.

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

Lunenburg CA, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JH, Gelderblom H.

Eur J Cancer. 2016 Feb;54:40-8. doi: 10.1016/j.ejca.2015.11.008. Epub 2015 Dec 21. Review.

PMID:
26716401
9.

Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.

Meulendijks D, Henricks LM, van Kuilenburg AB, Jacobs BA, Aliev A, Rozeman L, Meijer J, Beijnen JH, de Graaf H, Cats A, Schellens JH.

Cancer Chemother Pharmacol. 2016 Oct;78(4):875-80. doi: 10.1007/s00280-016-3137-0. Epub 2016 Aug 20.

PMID:
27544765
10.

Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.

van Staveren MC, van Kuilenburg AB, Guchelaar HJ, Meijer J, Punt CJ, de Jong RS, Gelderblom H, Maring JG.

Br J Clin Pharmacol. 2016 Mar;81(3):553-61. doi: 10.1111/bcp.12821. Epub 2016 Jan 8.

11.

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M.

Clin Pharmacol Ther. 2013 Dec;94(6):640-5. doi: 10.1038/clpt.2013.172. Epub 2013 Aug 29.

12.

[Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?].

Jedrzychowska A, Dołegowska B.

Ann Acad Med Stetin. 2013;59(2):48-53. Polish.

PMID:
25026750
13.

Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.

Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ, Schellens JH, Guchelaar HJ.

Pharmacogenomics. 2015;16(11):1277-86. doi: 10.2217/pgs.15.70. Epub 2015 Aug 12. Review.

PMID:
26265346
14.

[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].

Boisdron-Celle M, Morel A, Gamelin E.

Ann Biol Clin (Paris). 2010 Jan-Feb;68(1):27-32. doi: 10.1684/abc.2010.0394. Review. French.

15.

Dihydropyrimidine dehydrogenase deficiency caused by a novel genomic deletion c.505_513del of DPYD.

van Kuilenburg AB, Meijer J, Gökcay G, Baykal T, Rubio-Gozalbo ME, Mul AN, de Die-Smulders CE, Weber P, Mori AC, Bierau J, Fowler B, Macke K, Sass JO, Meinsma R, Hennermann JB, Miny P, Zoetekouw L, Roelofsen J, Vijzelaar R, Nicolai J, Hennekam RC.

Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):509-14. doi: 10.1080/15257771003730227.

PMID:
20544545
16.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM.

Br J Cancer. 2017 May 23;116(11):1415-1424. doi: 10.1038/bjc.2017.94. Epub 2017 Apr 20.

PMID:
28427087
17.

[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].

Ogura K.

Gan To Kagaku Ryoho. 2006 Aug;33(8):1041-8. Review. Japanese.

PMID:
16912518
18.

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?

Meulendijks D, Cats A, Beijnen JH, Schellens JH.

Cancer Treat Rev. 2016 Nov;50:23-34. doi: 10.1016/j.ctrv.2016.08.002. Epub 2016 Aug 13. Review.

PMID:
27589829
19.
20.

DPYD*2A mutation: the most common mutation associated with DPD deficiency.

Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB.

Cancer Chemother Pharmacol. 2007 Sep;60(4):503-7. Epub 2006 Dec 13.

PMID:
17165084

Supplemental Content

Support Center